Janssen Pharmaceutica NV
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: cardiovascular & metabolism, immunology, infectious diseases & vaccines, neuroscience, oncology and pulmonary hypertension.
More information: www.janssen.com »
In the initial EBiSC phase, Janssen advised on validation of the end-product, contributed to research on neurodegenerative diseases and, in 2017, took over the project leader's role from Pfizer. In EBiSC2, Janssen continues as the project leader to overall project management and business development. Upscaling of iPSC production technology to the needs of pharma industry will be one focus of Janssen. The Janssen Neuroscience department in EBiSC2 will be contributing to exploring iPSC to study Neurodegenerative Diseases, including Alzheimer's and Parkinson's disease. Another topic for Janssen will be the analysis of iPSC-derived cardiomyocytes for early toxicity assessments.